Patients The IgG preparations were obtained from the ten patients described in the preceding paper.4 Mice of both the AKR strain and the B6D2F1 hybrids were again used. The IgG was purified by the Rivanol ammonium sulphate method from plasma obtained during plasma exchange therapy.
An increased rate of acetylcholine receptor (AChR) degradation is thought to play an important role in the loss of end-plate AChRs which occurs in myasthenia gravis (MG). The rate of loss of 125I-abungarotoxin (a-butx)-labelled AChRs is increased both in myoblast cultures12 and in mice injected daily with IgG prepared from MG patients.3 We have confirmed these results but find that the increased rate of degradation is not an invariable result of human antibodies binding to mouse AChR at the end-plate.4 Moreover, even in those animals in which an increased rate of AChR degradation could be demonstrated the total number of acetylcholine receptors present at the end-plate after seven daily IgG injections was reduced less than predicted from the increased degradation rate.
These observations suggested that an increased rate of AChR synthesis might compensate for the increased rate of degradation that occurred with some IgG preparations4 and in this paper we describe the results of experiments designed to test this possibility. End-plate AChRs were first blocked by intrathoracic injection of non-radioactive a-butx. The animals then received daily injections of IgG. The rate of synthesis of new AChRs, free from a-butx, was measured at various time intervals by removing the diaphragms and incubating in radioactive a-butx in vitro. AChR synthesis was increased in animals injected with IgG preparations which increased AChR degradation.
Methods
Patients The IgG preparations were obtained from the ten patients described in the preceding paper.4 Mice of both the AKR strain and the B6D2F1 hybrids were again used. The IgG was purified by the Rivanol ammonium sulphate method from plasma obtained during plasma exchange therapy.
Synthesis ofjunctional AChRs ofmouse diaphragm in vivo Groups of animals (n = 10) were anaesthetised with halothane as previously described4 and a-butx (0-1 ,ug/g body weight) was injected into the left hemi-thorax. The amount of a-butx was critical as high doses led to an unacceptable mortality rate, and too low a dose caused insufficient blocking of the end-plate AChR. The exact amount injected was determined from preliminary experiments in which the animals were killed four hours later and their diaphragms incubated in vitro in 125I-a-butx as described in the preceding paper.4 The amount of a-butx injected was designed to block more than 90% of the mouse end-plate AChRs without killing the animals. The value for unblocked AChRs at 4 hours was used as Ro (see below).
The injected animals were killed at intervals over 1-9 days and the appearance of AChRs free -of a-butx was measured by incubation of the diaphragm in vitro in '25I_ a-butx as described previously.4 The number of observed AChRs (R obs) was expressed as a percentage of the initial total number present in diaphragms from untreated mice. The rate of synthesis of AChR was determined using the degradation constants (K) derived from the preceding paper: if RS is the actual number of AChRs synthesised by any particular time t, then RS = T.r where r is the frac-383 tional synthesis rate per day. Robs, the observed number of AChRs, is made up of r/K(l-exp(-Kt)), the 1) caused a significant increase in the rate of appearance of unlabelled AChRs.
For each experiment the synthesis rate constant was derived using the equation given in the methods. The effect of MG IgG on the. calculated rate of synthesis of AChR was not apparently related to the clinical state of the patient, to the anti-AChR titre against human or mouse AChR, or to the binding of human antibodies to the mouse AChR in vivo. However, those IgG preparations which had no effect upon the rate of AChR degradation in the previous experiments4 also had no effect on the rate of synthesis determined here, and the IgG preparations which had caused an acceleration of degradation also brought about an increased synthesis of new AChRs. This increased synthesis rate was clearly not due simply to the use of an increased degradation rate in the calculation since the actual observed number of newly synthesised AChRs was also increased (see fig 1) . When the results of experiments in both AKR and B6D2F1 mice were combined there was a significant positive correlation between the rates of degradation and synthesis (p < 0 01; fig 2) . The calculation of Rs, the actual number of AChRs synthesised, depends critically on the rate of degradation. Since degradation experiments could not be performed on the same animals as the synthesis experiments, this could be a source of error. The calculation also assumes that newly synthesised AChRs are degraded at the same rate as those labelled with 125j-a-butx in the degradation experiments. This is difficult to prove but the apparent first order kinetics for loss of 125I-a-butx from mammalian endplates observed by ourselves and others in degradation experiments6 7 suggests the existence of a single turnover rate rather than a mixture of different rates. One further factor is that the end-plate could become functionally inactive as a result of injection of the almost saturating amounts of a-butx combined with MG IgG; this might affect the rate of degradation and synthesis of the receptors which is now known to increase when end-plates are experimentally denervated by cutting the nerve.89 However there was no evidence of any denervation effect as judged by the lack of extra-junctional '251-a-butx binding in both these experiments and those reported in the preceding paper. 4 The rate of synthesis of acetylcholine receptors found in uninjected control animals was 
